Search | Clinical Trials Finder

The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 6:59 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 889–912 of 2,910 matching trials from the local directory fallback.

Filters: Baltimore, Maryland Clear all

Conditions: ALK Fusion Protein Expression, NSCLC Stage IV
Interventions: Peptide vaccine; Biological
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Aneurysm of Aorta, Thoracic, Aneurysmal Disease, Aorta, Thoracic Pathologies, Aortic Aneurysm, Aortic Aneurysm and Dissection, Aortic Diseases
Interventions: Rapidlink; Device
Lead sponsor: Vascutek Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 15
States / cities: Los Angeles, California • Aurora, Colorado • Washington D.C., District of Columbia + 11 more

Conditions: FSH Muscular Dystrophy, FSHD, FSHD - Facioscapulohumeral Muscular Dystrophy, FSHD1, FSHD2, Facio-Scapulo-Humeral Dystrophy, Facioscapulohumeral Dystrophy, Facioscapulohumeral Muscular Dystrophy, Facioscapulohumeral Muscular Dystrophy 1, Facioscapulohumeral Muscular Dystrophy 2, Facioscapulohumeral Muscular Dystrophy Type 1 (FSHD1), Fascioscapulohumeral Muscular Dystrophy, Fascioscapulohumeral Muscular Dystrophy Type 1, Fascioscapulohumeral Muscular Dystrophy Type 2, Landouzy Dejerine Dystrophy, Landouzy-Dejerine Muscular Dystrophy, Landouzy-Dejerine Syndrome
Interventions: AOC-1020, Placebo; Drug
Lead sponsor: Avidity Biosciences, Inc.; Industry
Eligibility: 16 Years to 70 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 14
States / cities: Orange, California • Palo Alto, California • Denver, Colorado + 11 more

Conditions: Cancer Harboring BRAF Alterations, HGG, LGG, Solid Tumors
Interventions: Plixorafenib; Drug
Lead sponsor: Fore Biotherapeutics; Industry
Eligibility: 8 Years and older
Enrollment: 254 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 30
States / cities: Beverly Hills, California • San Francisco, California • Westwood, Los Angeles, California + 23 more

Conditions: Bipolar I Disorder, Depression
Interventions: Cariprazine, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 380 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 69
States / cities: Bentonville, Arkansas • Anaheim, California • Beverly Hills, California + 54 more

Conditions: Parkinson Disease
Interventions: Not listed
Lead sponsor: Michael J. Fox Foundation for Parkinson's Research; Other
Eligibility: 30 Years and older
Enrollment: 4,500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2033
U.S. locations: 30
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 25 more

Conditions: Mitral Valve (MV) Regurgitation
Interventions: TRANSOM; Device
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years and older
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Lumbar Spinal Stenosis
Interventions: NIPT; Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 55 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Stroke
Interventions: Active movement training, Ankle torque and motion measurement, Gamed-based active movement training, Motor relearning training, Passive movement, Passive stretching; Device
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 30 Years to 85 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 3
States / cities: Baltimore, Maryland • Houston, Texas

Conditions: Extra-pulmonary Neuroendocrine Carcinoma, Neuroendocrine Neoplasms, Small Cell Lung Carcinoma
Interventions: BI 764532, dose 1, BI 764532, dose 2, Ventana DLL3 RxDx assay; Drug · Device
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 16
States / cities: Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 13 more

Conditions: Dementia, Pain
Interventions: Pain-CPG-EIT, Pain-CPG-Education Only; Behavioral · Other
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 60 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 11
States / cities: Baltimore, Maryland • Bel Air, Maryland • Columbia, Maryland + 5 more

Conditions: Knee Osteoarthritis
Interventions: Treatment for Knee OA; Procedure
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: Not listed
Enrollment: 10,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2033
U.S. locations: 19
States / cities: Phoenix, Arizona • Irvine, California • Los Angeles, California + 16 more

Conditions: Healthy
Interventions: Placebo, Psilocybin; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Aging, Depressive Symptoms, Pain
Interventions: SPARK; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 50 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Chronic Low-back Pain
Interventions: Standardized Education, Telerehabilitation; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 434 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Baltimore, Maryland • Salisbury, Maryland

Conditions: Antiphospholipid Syndrome (APS), Behçet's Syndrome (BS), Bullous Pemphigoid (BP), Dermatomyositis (DM), Immune Thrombocytopenia (ITP), Immune-mediated Necrotizing Myopathy (IMNM)
Interventions: RAY121; Drug
Lead sponsor: Chugai Pharmaceutical; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 11
States / cities: Orange, California • Baltimore, Maryland • Lake Success, New York + 8 more

Conditions: Solid Tumors
Interventions: Cetuximab, FOLFIRI, FOLFOX, GEMNabP, INCA33890, INCB161734, Retifanlimab, mFOLFIRINOX; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 710 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 13
States / cities: Phoenix, Arizona • Palo Alto, California • Santa Monica, California + 9 more

Conditions: Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Small Cell Lung Carcinoma, Stomach Neoplasms
Interventions: 5-Fluorouracil (5-FU), Leucovorin (LV), Oxaliplatin, PF-08046050, bevacizumab; Drug
Lead sponsor: Seagen, a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 914 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 21
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Duarte, California + 13 more

Conditions: Non-Small Cell Lung Cancer
Interventions: ALK-inhibitor or RET-inhibitor, BNT116, BNT316, Bispecific antibody for PD-L1 and VEGF-A, Carboplatin, Cemiplimab, Docetaxel, Osimertinib, Paclitaxel, anti-B7-H3 antibody conjugated to topoisomerase I inhibitor, anti-HER3 antibody conjugated to topoisomerase I inhibitor; Biological · Drug
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2031
U.S. locations: 6
States / cities: Lexington, Kentucky • Louisville, Kentucky • Baltimore, Maryland + 3 more

Conditions: Post Operative Surgical Site Infection
Interventions: Standard of care, Vancomycin and Tobramycin; Drug
Lead sponsor: Major Extremity Trauma Research Consortium; Other
Eligibility: 18 Years to 64 Years
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 31
States / cities: Redwood City, California • San Francisco, California • Aurora, Colorado + 25 more

Conditions: Colorectal Cancer
Interventions: Capecitabine, Cemiplimab, Fianlimab, Oxaliplatin, REGN7075; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Renal Cell Carcinoma (Kidney Cancer)
Interventions: 111In-XYIMSR-01; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Sudden Infant Death, Sudden Unexplained Infant Death
Interventions: ISA-MI, Standard of Care (SOC); Behavioral · Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 3 Days to 75 Years
Enrollment: 350 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Chronic Myelogenous Leukemia - Chronic Phase
Interventions: TKIs; Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2033
U.S. locations: 17
States / cities: Birmingham, Alabama • Stockton, California • Torrance, California + 13 more

Search by objective public record fields.

Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC

A Study to Evaluate the Safety and Effectiveness of the Rapidlink Device When Used in Patients Undergoing an Open Surgical Procedure to Repair the Aorta

A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.

PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort

Transventricular Off-pump Mitral Valve Repair

Lumbosacral Spinal Stenosis - Non-Invasive Postural Therapy for Older Adult Veterans

Facilitating Neuroplastic Changes of Acute Stroke Survivors

DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers

Testing the Pain Clinical Practice Guideline

Innovations in Genicular Outcomes Registry

Effects of Psilocybin on Electrophysiology and the Dynamic Content of Thought

Strength and Pain-Coping Through Resilience and Knowledge

Improving Health for Patients With Chronic Low Back Pain in Rural Communities Through Telerehabilitation

Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)

A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors

Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer

Evaluation of a New Strategy for Protocolized Antibiotic Care for Severe Open Fractures: SEXTANT 2

Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer

Study of 111In-XYIMSR-01 SPECT/CT in Patients With Metastatic Clear Cell Renal Cell

Improving Pediatrician Counseling About Infant Safe Sleep Using the Electronic Medical Record

A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy